Organic Consumers Association


Previous Page

Click here to print this page

Make a Donation!


FDA's Corrupt Practices on Drugs & GE Foods Aid Big Corporations & Threaten Public Health

GM WATCH daily

The events described below, which have led the The Lancet to write of
"lethal weaknesses in the U.S. Food and Drug Administration's regulatory
oversight", should not come as a surprise. They are yet another clear illustration as
to whose side the FDA is on.

Those scientists within the FDA who are known to have raised safety concerns
about (Genetically Modified Organisms) GMOs never stood a chance. The FDA's
own records reveal it declared GM foods to be safe in the face of broad disagreement from its own experts while the FDA claimed scientific consensus. The FDA has even acknowledged it has been operating under a government policy "to foster" the U.S.
biotechnology industry.

The articles below about drug regulation in the U.S., and in particular the
gagging and denigration of the FDA's senior drug safety officer, Dr David
Graham, are not describing an isolated instance even in the drug safety

What's happening to Graham was almost exactly paralleled with
GlaxoSmithKline's Paxil and selective serotonin reuptake inhibitors
(SSRIs). In that case, the FDA refused to let Dr. Andrew Mosholder, of the FDA
Office of Drug Safety, present to an advisory panel the findings of an analysis of
clinical trials related to antidepressant use in children. That analysis
had found a heightened risk of suicidality (suicidal tendencies). Indeed,
according to an investigation by Sen. Charles Grassley (see item 2) the FDA
actually tried to get Mosholder to present data that deceptively
underrepresented the risk of suicidality.

What has emerged about the FDA gives added significance to the notorious
comment made by Phil Angell, when Monsanto's director of corporate

"Monsanto should not have to vouchsafe the safety of biotech food. Our
interest is in selling as much of it as possible. Assuring its safety is
the FDA's job." - New York Times, October 25, 1998

As Dr. Herbert Ley, Former FDA Commissioner, once put it, "What the FDA is
doing and what the public thinks it's doing are as different as night and

1.Merck: 55,000 Dead
2.FDA scientist censored
3.Regulators Are Trying to Quash Study, Senator Says

1.Merck: 55,000 Dead

It's not as if people in power didn't know about the impending disaster ?
what David Graham, a Food and Drug Administration (FDA) drug safety
official, calls "maybe the single greatest drug-safety catastrophe in the
history of this country."

Testifying before a Senate committee in November, Dr. Graham put the number
in the United States who had suffered heart attacks or stroke as result of
taking the arthritis drug Vioxx in the range of 88,000 to 139,000. As many
as 40 percent of these people, or about 35,000-55,000, died as a result,
Graham said.

The unacceptable cardiovascular risks of Vioxx were evident as early as 2000
? a full four years before the drug was finally withdrawn from the market
by its manufacturer, Merck, according to a study released by the Lancet,
the British medical journal.

"This discovery points to astonishing failures in Merck's internal systems
of post-marketing surveillance, as well as to lethal weaknesses in the U.S.
Food and Drug Administration's regulatory oversight," Lancet editors wrote.

...Dr. Graham, the federal drug-safety reviewer, continues to seek to
his study demonstrating the dangers of Vioxx, but he has been delayed and
demeaned by top officials at the Food and Drug Administration.

At the Senate hearing, Dr. Graham said that the FDA "as currently configured
is incapable of protecting America against another Vioxx," because of ties
between agency reviewers and the pharmaceutical industry. Graham says that
as a result of his testimony, his bosses have threatened to toss him out of
the FDA's drug safety unit.

At the Senate hearing, Graham said that at least five medications currently
on the market pose such risks that their sale ought to be limited or

In November 2004, named David Graham "face of the year." We join
with Forbes in saluting Graham "for his steadfast advocacy of drug safety
and his willingness to blow the whistle on his bosses."

2.Cox-2s safety summit sees FDA scientist censored
By Katherine Griffiths in New York and Stephen Foley in London
The Independent, 16 February 2005

David Graham, the high-profile scientist at America's Food and Drug
Administration, has been banned from presenting new information about a
controversial type of painkiller at a three-day summit on their safety
starting today.

Dr Graham, who works in the FDA's office of drug safety, said yesterday that
he had been "threatened with being called insubordinate" by the FDA when he
said he wanted to include the findings of an unpublished study he has
completed as part of his testimony on Cox-2 inhibitors.

The FDA has organised the series of hearings, which will include evidence
from drug makers and scientists, in Washington in response to mounting
concerns about Cox-2s and to allegations that the agency has been too slow
to deal with possible dangers associated with the drugs. Last September,
the US pharmaceuticals giant Merck withdrew Vioxx after a study showed the
blockbuster increased the risk of heart disease five-fold in patients on a
high dose.

Relations between Dr Graham and his employer have been strained since he
spoke out against the way the FDA handled Vioxx, which he said caused heart
problems in up to 140,000 patients.

Last November, the FDA publicly repudiated comments by Dr Graham naming five
drugs, including AstraZeneca's cholesterol lowering pill Crestor and GSK's
asthma drug Serevent, that he thought could be too dangerous for use.

The agency argued that it has struck the right balance of benefits and risks
when assessing new drugs for launch, but it has been accused of being too
close to the drug industry and has faced political calls to split its
safety monitoring functions into an agency separate from the drug approvals
process. ------

3.Drug Regulators Are Trying to Quash Study, Senator Says
New York Times, February 12, 2005

WASHINGTON, Feb. 11 - The tension and intrigue surrounding a crucial federal
drug advisory committee meeting next week, already high, reached a boil on
Friday when Senator Charles E. Grassley charged that top federal drug
regulators intended to suppress an important study.

The panel has been convened to discuss whether Celebrex and Bextra, heavily
selling arthritis pills from Pfizer, hurt the heart and are worth their
potential risks. But top officials of the Food and Drug Administration have
forbidden Dr. David Graham, a drug-safety officer at the agency, to discuss
before the panel a large study of that very question, said Dr. Gurkirpal
Singh of Stanford University School of Medicine, Dr. Graham's co-author.

"We have significant new information that will alter the thinking about
these drugs," Dr. Singh said. "I don't understand why they won't let us present
this information."

Mr. Grassley, an Iowa Republican, wrote a letter Friday to the agency's
acting commissioner, Dr. Lester Crawford, demanding to know by Monday the
reason for the agency's decision.

Dr. Graham expressed frustration that F.D.A. officials had instructed him
not to discuss the new study in a presentation he is scheduled to give to the
committee on Thursday.

"This study bears directly on the whole reason why this advisory meeting is
being held in the first place," Dr. Graham said.

Agency officials told him the study had not yet been properly vetted, he

A spokesman for the agency denied that Dr. Graham had been barred from
presenting the new findings. He said that agency officials had simply
expressed a preference "that he rely on published literature in his talk,
but that it was his call if he wanted to offer data from his new study."

The latest charge suggests that the panel will render judgment not only on
the safety of Celebrex and Bextra but also on how well the F.D.A. is doing
its job.

A series of controversies have called into question whether the agency has
the tools or the will to protect patients' health.

Some in Congress, including Mr. Grassley, are calling for fundamental
changes at the agency. Drug-safety advocates claim that top agency officials are
far too cozy with drug makers. Agency officials say they are doing a good job.

Both sides point to the story of Vioxx, a pain pill similar to Celebrex and
Bextra that Merck withdrew from the market in September, an action that
will also be discussed at the hearing.

"There seems to be this view that we did something wrong with Vioxx," Dr.
Robert Temple, director of the agency's office of medical affairs, said in
an interview. "What exactly is the thing that we did wrong? Approving it?
Making them do a 6,000-patient study to get a claim? What?"

Mr. Grassley had a quick answer. "The Vioxx disaster and its aftermath have
shaken the public's confidence in the Food and Drug Administration," he
said, in part because, instead of listening to its best scientists, the
agency is "sitting down to negotiate with drug companies."

Vera Sharav, president of the Alliance for Human Research Protection, said
that the Vioxx story demonstrated that "the F.D.A. has abandoned its public
responsibility to protect us from unsafe drugs and is standing by as drug
companies market lethal drugs."

A Merck spokeswoman said that the company had acted appropriately in its
research, marketing and eventual withdrawal of Vioxx.

Pfizer representatives say that studies show that Celebrex and Bextra are

There is a sense of deja vu to Dr. Singh's latest charge. The agency
convenedan advisory panel a year ago to discuss whether antidepressants cause
children and teenagers to become suicidal. Dr. Andrew Mosholder, another
drug-safety officer for the agency, had concluded that the drugs did
increase the risks of suicide. Top officials were skeptical of his findings
and would not let him testify about his data before the panel.

A second study eventually confirmed Dr. Mosholder's conclusions, but the
agency's refusal to let Dr. Mosholder testify caused a firestorm of
criticism and prompted Mr. Grassley to begin an investigation of the

The advisory panel will meet for three days beginning on Wednesday. It
already has a mountain of data to sort through.

At the end of the hearings, the committee will be asked whether Celebrex and
Bextra should be withdrawn or whether warnings on their labels should
simplybe strengthened.

The committee may debate whether the withdrawal of Vioxx was appropriate.
Andthe committee will also discuss what, if any, studies of the drugs should
beundertaken, according to F.D.A. documents.